Linzatin M Tablet contains Metformin 500mg + Linagliptin 2.5mg, a dual-action oral antidiabetic therapy for type 2 diabetes management. Metformin reduces hepatic glucose production and enhances insulin sensitivity, while Linagliptin, a DPP-4 inhibitor, increases incretin levels to stimulate insulin release and reduce glucagon secretion.
This tablet is part of the diabetes care segment, providing a convenient combination therapy that targets multiple mechanisms of glucose regulation. Its formulation is ideal for patients needing complementary glycemic control without increasing pill burden.
Linzatin M Tablet is commonly prescribed by endocrinologists, general physicians, hospitals, and clinics, ensuring high demand for PCD pharma franchise and B2B distribution. Its dual-action mechanism supports patient adherence, repeat prescriptions, and improved glycemic outcomes.
For PCD pharma franchise and B2B partners, Linzatin M Tablet represents a profitable and in-demand opportunity. Strong hospital, clinic, and retail demand makes it suitable for domestic distribution, export, and third-party manufacturing, ensuring sustainable growth and attractive margins.